Bristol-Myers Squibb (BMY) Tops Q3 EPS by 17c, Beats on Revenue, Offers FY22 Revenue Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. ZETA
9. DAL
10. TMUS

Go back to Bristol-Myers Squibb (BMY) Tops Q3 EPS by 17c, Beats on Revenue, Offers FY22 Revenue Guidance

Bristol Myers Squibb Reports Third Quarter Financial Results for 2022 

October 25, 2022 7:31 PM EDT

Reports Third Quarter Revenues of $11.2 Billion Delivers Strong Revenue Growth of 8% from In-Line Products and New Product Portfolio; or 13% When Adjusted for Foreign Exchange Posts Third Quarter Earnings Per Share of $0.75 and Non-GAAP EPS of $1.99; Includes Net Increase of $0.02 Per Share for GAAP and Non-GAAP EPS Due to Acquired IPRD1 Charges and Licensing Income Bolsters New Product Portfolio with FDA Approval for SotyktuTM, a First-in-Class TYK2 inhibitor for Adults with Moderate-to-Severe Plaque Psoriasis Continues to Progress Product Pipeline with Significant Regulatory and Clinical Milestones Completes Acquisition of... More